SEQUENOM INC. NEW läuft weiter megamässsig!!

http://www.ariva.de/news/...ncial-Results-And-Conference-Call-5001189 GrB  

http://www.ariva.de/news/...lts-For-The-First-Quarter-Of-2014-5022329 GrB  

Sequenom, Inc. Announces Date Of First Quarter 2014 Financial Results And Conference Call
13:05 17.04.14

PR Newswire

SAN DIEGO, April 17, 2014

SAN DIEGO, April 17, 2014 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced it will report financial results for the first quarter of 2014 after closing of the NASDAQ Global Market on Thursday, May 1, 2014.

A conference call hosted by Harry F. Hixson, Jr., Ph.D., Chairman and CEO, and other members of senior management will take place on the same day at 5:00 pm EDT (2:00 pm PDT) and will be webcast live on the Sequenom Web site.

To access the live teleconference call, dial 877-883-0383 in the U.S. and Canada, and 412-902-6506 for other international callers. Please use code 4130222. For interested parties unable to listen to the live webcast, a teleconference replay will be available through Friday, May 16, 2014. The replay will be accessible by dialing 877-344-7529 or 412-317-0088 internationally, and entering the conference number 10044794.

The conference call webcast is accessible through the "Investors" section of the Sequenom Web site at www.sequenom.com/invest. An online replay will be available following the initial broadcast until Friday, May 16, 2014.

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genomic and genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostic markets. Website: http://www.sequenom.com/.

SEQUENOM logo.
Logo - http://photos.prnewswire.com/prnh/20040415/SQNMLOGO

SOURCE Sequenom, Inc.


Quelle: PR Newswire  

http://www.ariva.de/news/...ncial-Results-And-Conference-Call-5100539 GrB  

Sequenom Laboratories Expands International Noninvasive Prenatal Testing Services To Broader Population With VisibiliT™ Test
13:05 21.07.14

PR Newswire

SAN DIEGO, July 21, 2014

SAN DIEGO, July 21, 2014 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that its wholly owned subsidiary, Sequenom Laboratories, will soon launch  the VisibiliT™ laboratory-developed test in international markets. The VisibiliT test utilizes maternal age, fetal fraction and the relative amount of chromosomal material for chromosomes 21 and 18 to generate a highly accurate, personalized risk score. The VisibiliT test is for pregnant women who want information about common fetal trisomies (Down syndrome and Edwards syndrome), have a single gestation pregnancy, and whose pregnancies are considered to be at average risk. The test can also report fetal gender. With the VisibiliT test, Sequenom Laboratories fulfills its goal to expand its noninvasive prenatal testing (NIPT) menu with the development of a low-cost test by year-end to facilitate international access.

"This is an important development because it makes an excellent test much more affordable and accessible to a wider spectrum of pregnant women throughout the world," said Professor Kypros Nicolaides, M.D., director of the Fetal Medicine Foundation and the Harris Birthright Research Centre for Fetal Medicine at King's College Hospital in London.

Performance of the VisibiliT test was determined by a clinical evaluation study of over 1,000 samples, and demonstrated a greater than 99% sensitivity and specificity for trisomies 21 and 18. A poster entitled, 'Application of risk-score analysis to low-coverage whole genome sequencing data for the noninvasive detection of trisomy 21 and trisomy 18,' will be presented at the 18th International Conference on Prenatal Diagnosis and Therapy (ISPD) taking place July 20-23 in Brisbane, Australia.

Building a global portfolio of laboratory-developed tests for noninvasive prenatal assessment

Sequenom Laboratories is the first test service provider to offer two distinct NIPT options—MaterniT21™ PLUS and VisibiliT—enabling greater testing access and flexibility for providers and patients.

"The launch of the VisibiliT test is an important achievement for the company, as we are expanding our noninvasive prenatal testing menu to provide additional choices to better serve the broader prenatal testing community," said William Welch, Chief Executive Officer of Sequenom, Inc. "We are committed to innovating and building upon our market-leading NIPT services and solutions as we continue to provide valuable information to health care professionals and their patients around the world."

The VisibiliT test will be available to international markets beginning in August. Sequenom Laboratories will continue ongoing discussions with payors in the U.S. and is prepared to offer the test in the U.S. as insurance coverage develops.  

The technology at the forefront of prenatal testing

Sequenom Laboratories first pioneered the use of NIPT in 2011, with the introduction of the MaterniT21 PLUS laboratory-developed test that's benefited more than 250,000 pregnant women worldwide. Because of this advance, thousands of pregnant women have avoided potentially unnecessary invasive procedures while still gaining critical genetic information about the health of their pregnancies. The VisibiliT test maintains the same Sequenom Laboratories' commitment to quality and accuracy that's featured in the MaterniT21 PLUS test.

Using a maternal blood sample, the VisibiliT and MaterniT21 PLUS tests analyze chromosomal material in cell-free fetal DNA of pregnant women. The VisibiliT test reports a risk score for common fetal chromosomal abnormalities, specifically trisomies 21 and 18, as well as fetal gender. The MaterniT21 PLUS test, by contrast, reports both common and rare fetal chromosomal abnormalities—from trisomies 21, 18 and 13 to fetal sex aneuploidies, trisomies 16, 22, fetal gender and select microdeletions.

Both tests were developed, validated and are performed exclusively by Sequenom Laboratories. Test results are provided to the ordering health care provider.

Sequenom Laboratories Presentations at ISPD

Tuesday, July 22, 2014, Session 6: Screening for aneuploidy / NIPT

11:06-11:16 a.m. – NIPT 2.0: Identification of 22q microdeletions by noninvasive prenatal testing; Presenter: Juan-Sebastian Saldivar
11:39 – 11:45 a.m. – Genome wide analysis of sub-chromosomal copy number variations using NIPT in over 4500 patients; Presenter: Dirk van den Boom
Sequenom Scientific Posters at ISPD

Characterization and targeted isolation of circulating cell-free DNA for the noninvasive prenatal MaterniT21™ PLUS LDT
Noninvasive detection of a balanced fetal translocation from maternal plasma
Detection of fetal subchromosomal abnormalities by sequencing circulating cell-free DNA from maternal plasma
Factors affecting levels of circulating cell-free fetal DNA in maternal plasma and their implications for noninvasive prenatal testing
Evaluation of targeted methodologies for the noninvasive detection of fetal aneuploidies
Prenatal detection of fetal aneuploidy on the Ion Torrent proton platform
Application of risk score analysis to low-coverage whole genome sequencing data for the noninvasive detection of trisomy 21 and trisomy 18
About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genomic and genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve molecular diagnostic markets. Website: www.sequenom.com.

About Sequenom Laboratories

Sequenom Laboratories, a CAP accredited and CLIA-certified molecular diagnostics laboratory, has developed a broad range of laboratory tests, with a focus on prenatal and ophthalmological diseases and conditions. Branded under the name HerediT™, MaterniT21™ PLUS, RetnaGene™, SensiGene™ and VisibiliT™, these molecular genetic laboratory-developed tests provide early patient management information for obstetricians, geneticists, maternal fetal medicine specialists and ophthalmologists. Sequenom Laboratories is changing the landscape in genetic disorder diagnostics using proprietary cutting edge technologies.

SEQUENOM®, HerediT™, MaterniT21™ PLUS, RetnaGene™, SensiGene™ and VisibiliT™, are trademarks of Sequenom, Inc.  All other trademarks and service marks are the property of their respective owners.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Sequenom's expected launch and availability in August of Sequenom Laboratories' VisibiliT test, the impact and benefits of the test including affordability and accessibility to a wider spectrum of pregnant women throughout the world, Sequenom's commitment to innovating and building upon its market leading NIPT services and solutions and its ability to continue to provide valuable information to health care professionals and their patients, and Sequenom Laboratories' plans to continue ongoing discussions with payors in the U.S. and its preparation to offer the test in the U.S. as insurance coverage develops, Sequenom's commitment to improving healthcare through revolutionary genomic and genetic analysis solutions, and Sequenom Laboratories' changing the landscape in genetic disorder diagnostics, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with Sequenom's ability to develop and commercialize new technologies and products, particularly new technologies such as prenatal and other diagnostics and laboratory developed tests such as the VisibiliT test, Sequenom's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals, ongoing patent litigation, and other risks detailed from time to time in Sequenom, Inc.'s most recent Quarterly and Annual Reports on Securities and Exchange Commission Forms 10-Q and 10-K, respectively, and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Sequenom undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

SEQUENOM logo.
Logo - http://photos.prnewswire.com/prnh/20040415/SQNMLOGO

SOURCE Sequenom, Inc.


Quelle: PR Newswire  

on the Enhanced Sequencing Series for the MaterniT21™ Plus Laboratory-Developed Test At 18th International Conference on Prenatal Diagnosis and Therapy
13:05 22.07.14

PR Newswire

SAN DIEGO, July 22, 2014

SAN DIEGO, July 22, 2014 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced its wholly owned subsidiary, Sequenom Laboratories, will soon begin reporting on the presence of three additional clinically relevant subchromosomal microdeletions as part of the Enhanced Sequencing Series (ESS) for its MaterniT21™ PLUS laboratory-developed test. The microdeletions added include 11q deletion (Jacobsen syndrome), 8q deletion (Langer-Giedion syndrome), and 4p deletion (Wolf-Hirschhorn syndrome) and will be reported as an additional finding when a positive result is detected. New study data on the Enhanced Sequencing Series was presented at the 18th International Conference on Prenatal Diagnosis and Therapy (ISPD) in Brisbane Australia.

SEQUENOM logo.
"The MaterniT21 PLUS test has helped change how we treat our prenatal patients, and its ability to screen for several microdeletions exemplifies the growth and potential of this technology," said Jeff Chapa, MD, Head of the Section of Maternal-Fetal Medicine in Cleveland Clinic Department of Obstetrics and Gynecology. "With the Enhanced Sequencing Series, I can provide my patients with this clinically relevant information as early as 10 weeks into a pregnancy."

These microdeletions are associated with various clinical conditions that can result in physical and developmental issues. Jacobsen syndrome, which is caused by a deletion on the long arm of chromosome 11, is characterized by growth restriction, developmental delay, distinctive facial features, and a bleeding disorder called Paris-Trousseau syndrome. Langer-Giedion syndrome, caused by a deletion on the long arm of chromosome 8, is characterized by bone abnormalities and may be associated with developmental delays. Wolf-Hirschhorn syndrome is caused by a deletion on the short arm of chromosome 4 and is characterized by distinctive craniofacial anomalies, growth restriction, developmental delay, hearing loss and seizures.

This expansion complements the MaterniT21 PLUS test original Enhanced Sequencing Series of clinically relevant microdeletions which Sequenom Laboratories began reporting in October 2013. Included were 22q11.2 deletion (DiGeorge syndrome), 5p minus (Cri-du-chat syndrome), 15q deletion (Prader-Willi/Angelman syndromes), 1p36 deletion syndrome, as well as two additional trisomies, (trisomy 16 and 22).

"Leveraging our advanced, whole genome technology, we are able to offer more comprehensive prenatal information to health care providers and their patients," said Dirk van den Boom, PhD, Chief Scientific and Strategy Officer at Sequenom, Inc. "We have received very positive response to the Enhanced Sequencing Series. This set of microdeletions added to our MaterniT21 PLUS test is the next extension of the Enhanced Sequencing Series and continues our path towards the vision of a noninvasive fetal karyotype."

Sequenom Laboratories first pioneered the use of noninvasive prenatal testing (NIPT) in 2011. With this expansion, the MaterniT21 PLUS test is the first-of-its-kind NIPT to provide these comprehensive results from a maternal blood draw. The MaterniT21 PLUS test was developed, validated and is performed exclusively by Sequenom Laboratories.

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genomic and genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve molecular diagnostic markets. Website: www.sequenom.com.

About Sequenom Laboratories

Sequenom Laboratories, a CAP accredited and CLIA-certified molecular diagnostics laboratory, has developed a broad range of laboratory tests, with a focus on prenatal and ophthalmological diseases and conditions. Branded under the name HerediT™, MaterniT21™ PLUS, RetnaGene™, SensiGene™ and VisibiliT™, these molecular genetic laboratory-developed tests provide early patient management information for obstetricians, geneticists, maternal fetal medicine specialists and ophthalmologists. Sequenom Laboratories is changing the landscape in genetic disorder diagnostics using proprietary cutting edge technologies.

SEQUENOM®, HerediT™, MaterniT21™ PLUS, RetnaGene™, SensiGene™ and VisibiliT™, are trademarks of Sequenom, Inc.  All other trademarks and service marks are the property of their respective owners.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Sequenom's expected launch of Sequenom Laboratories' Enhanced Sequencing Series for its MaterniT21 PLUS test, the impact and benefits of the Enhanced Sequencing Series on patients and health care providers, Sequenom's vision of a noninvasive fetal karyotype, Sequenom's commitment to improving healthcare through revolutionary genomic and genetic analysis solutions, and Sequenom Laboratories' changing the landscape in genetic disorder diagnostics, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with Sequenom's ability to develop and commercialize new technologies and products, particularly new technologies such as prenatal and other diagnostics and laboratory developed tests, Sequenom's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals, ongoing patent litigation, and other risks detailed from time to time in Sequenom, Inc.'s most recent Quarterly and Annual Reports on Securities and Exchange Commission Forms 10-Q and 10-K, respectively, and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Sequenom undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Logo - http://photos.prnewswire.com/prnh/20040415/SQNMLOGO

SOURCE Sequenom, Inc.


Quelle: PR Newswire  

Medical Laboratories
22:15 29.07.14

PR Newswire

SAN DIEGO, July 29, 2014

SAN DIEGO, July 29, 2014 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company that provides innovative genetic analysis solutions, and Mayo Medical Laboratories (MML), the third-largest provider of esoteric laboratory services in the United States, have announced a license agreement for noninvasive prenatal testing patents and applications.

"We have great appreciation for Mayo Clinic's commitment to research, innovation, and patient care, and we welcome the opportunity to partner with the organization's leading clinical research laboratory to expand patient access to this revolutionary technology," said William Welch, chief executive officer of Sequenom, Inc.

Sequenom Laboratories first pioneered the use of noninvasive prenatal testing in 2011 with the introduction of the MaterniT21™ PLUS laboratory-developed test that has helped more than 250,000 pregnant women worldwide who are at a high risk for fetal chromosomal abnormalities. A December 2012 joint committee opinion from the American Congress of Obstetricians and Gynecologists and the Society of Maternal Fetal Medicine supports the use of cell-free fetal DNA testing as an option for primary screening for pregnant women at increased risk of aneuploidy (abnormal chromosomal number), including those 35 years of age or older or who have a history of ultrasound abnormalities in pregnancy.

Terms of the agreement were not disclosed.

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving health care through revolutionary genomic and genetic analysis solutions. Sequenom develops innovative technologies, products, and diagnostic tests that target and serve molecular diagnostic markets. Web site: www.sequenom.com

About Sequenom Laboratories

Sequenom Laboratories, a CAP-accredited and CLIA-certified molecular diagnostics laboratory, has developed a broad range of laboratory tests, with a focus on prenatal and ophthalmological diseases and conditions. Branded under the names HerediT™, MaterniT21™ PLUS, RetnaGene™, SensiGene™ and VisibiliT™, these molecular genetic laboratory-developed tests provide early patient-management information for obstetricians, geneticists, maternal fetal medicine specialists, and ophthalmologists. Sequenom Laboratories is changing the landscape in genetic-disorder diagnostics using proprietary cutting-edge technologies.

About Mayo Medical Laboratories and the Mayo Clinic Department of Laboratory Medicine and Pathology

Mayo Medical Laboratories is the largest for-profit company associated with Mayo Clinic, the world-renowned health care organization located in Rochester, Minnesota. MML is the third-largest provider of esoteric laboratory services in the United States and serves more than 5,000 clients in 130 countries. Mayo Clinic's Department of Laboratory Medicine and Pathology maintains an active diagnostic test-development program. These activities also incorporate technologies from collaborations with diagnostic and biotechnology companies. Mayo Clinic utilizes these proven diagnostic technologies in the care of its patients and offers them to health care institutions through Mayo Medical Laboratories. Revenue from this testing is used to support medical education and research at Mayo Clinic.

Mayo Clinic is a nonprofit worldwide leader in medical care, research, and education for people from all walks of life. For more information, visit mayoclinic.com or mayoclinic.org/news.  Journalists can become a member of the Mayo Clinic News Network for the latest health, science, and research news and access to video, audio, text, and graphic elements that can be downloaded or embedded.

SEQUENOM®, HerediT™, MaterniT21™ PLUS, RetnaGene™, SensiGene™, and VisibiliT™ are trademarks of Sequenom, Inc. All other trademarks and service marks are the property of their respective owners.

Forward-Looking Statement

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Sequenom's expectations related to future performance under the agreement between Sequenom and Mayo Medical Laboratories, the expected or potential benefits and impact of the agreement on Sequenom, patients and physicians, Sequenom's commitment to improving health care through revolutionary genomic and genetic analysis solutions, and Sequenom Laboratories' changing the landscape in genetic disorder diagnostics, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with market demand for and acceptance and use of technology and tests such as the MaterniT21 PLUS test, reliance upon the collaborative efforts of other parties and licensees such as Mayo Medical Laboratories, healthcare providers and others, Sequenom or third parties obtaining or maintaining regulatory approvals that impact Sequenom's business, government regulation particularly with respect to diagnostic products and laboratory developed tests, publication processes, the performance of designed product enhancements, Sequenom's ability to develop and commercialize technologies and products, particularly new technologies such as noninvasive prenatal diagnostics and laboratory developed tests, Sequenom's financial position, the timing and amount of reimbursement that Sequenom Laboratories receives from payors for its laboratory developed tests, Sequenom's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, litigation involving Sequenom, and other risks detailed from time to time in Sequenom's most recently filed reports on Form 8-K, its most recently filed Quarterly Report on Form 10-Q and its Annual Report on Form 10-K for the year ended December 31, 2013, and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Sequenom undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

SEQUENOM logo.
Logo - http://photos.prnewswire.com/prnh/20040415/SQNMLOGO

SOURCE Sequenom, Inc.


Quelle: PR Newswire  

http://www.ariva.de/news/...ts-For-The-Second-Quarter-Of-2014-5115969 GrB  

Sequenom, Inc. Announces Participation At The 2014 Wedbush Securities Life Sciences Management Access Conference
13:05 05.08.14

PR Newswire

SAN DIEGO, Aug. 5, 2014

SAN DIEGO, Aug. 5, 2014 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced the Company's participation at the 2014 Wedbush Securities Life Sciences Management Access Conference at Le Parker Meridien in New York, NY on August 12-13, 2014.

William Welch, President and Chief Operating Officer, will present on Tuesday, August 12, beginning at 4:15 p.m. ET to provide an overview of and update on the Company. The presentation is expected to last approximately 30 minutes and will be webcast live through the "Invest" section of the Sequenom Web site at www.sequenom.com. An audio replay will be available for 30 days following the initial broadcast.

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving health care through revolutionary genomic and genetic analysis solutions. Sequenom develops innovative technologies, products, and diagnostic tests that target and serve molecular diagnostic markets. Web site: www.sequenom.com

SEQUENOM logo.
Logo - http://photos.prnewswire.com/prnh/20040415/SQNMLOGO

SOURCE Sequenom, Inc.


Quelle: PR Newswire  

Bucheinsicht
http://www.ariva.de/sequenom-aktie/times_and_sales?boerse_id=40 GrB  

Nasdaq Preis pro share 3,81 $ Schleife 3.700 spread 0,26% buran und MfG und so jung wie heute sehen wa uns nie wiedaaaaaa ..::hopshopshopshopshops HALLO  

www.sequenom.com

buran und MfG  

be a fact of life. But for us, it's never a fact of science. We’re 100% committed to scientific integrity in every product and service we offer. No exceptions. Ever. If you want the power of science on your side, it's Sequenom. http://www.sequenom.com/
 

out of the lab.
http://www.sequenom.com/...lity-science-means-performance-and-out-lab  

..yöah  

Sequenom (NASDAQ:SQNM) represents an investment in tomorrow. From Sequenom Laboratories' groundbreaking testing services for the healthcare industry, to Sequenom Biosciences' best-in-class products for the research and clinical laboratory communities, to our global offices in Europe and Asia, the company is actively moving the genetic revolution forward in ways that will impact millions of patients. http://www.sequenom.com/...lity-science-means-performance-and-out-lab

 

..yöah  

deeply in "Quality of Science." We simply tolerate no compromise in the scientific basis or measurably superior performance of our products. This is why we can confidently state our leadership in the life sciences, and our full intention to engineer a new tomorrow. http://www.sequenom.com/...lity-science-means-performance-and-out-lab
 

..yöah  

http://www.sequenom.com/invest/events-and-webcasts GrB  

..yöah  

..yöah  

DANKE...  

http://www.sequenom.com/invest/corporate-governance GrB  

nu los los los